Biochemical and Anti-Triple Negative Metastatic Breast Tumor Cell Properties of Psammaplins

• Main Authors: Yu-Dong Zhou, Jun Li, Lin Du, Fakhri Mahdi, Thuy P. Le, Wei-Lun Chen, Steven M. Swanson, Kounosuke Watabe, Dale G. Nagle
• Format: Article
• Language: English
• Published: MDPI AG 2018-11-01
• Series: Marine Drugs
• Subjects: psammaplins; HDAC inhibitors; HIF; VEGFA; anti-metastatic; metastatic organotropism; bone metastases; triple-negative breast cancer; metastases-specific antitumor agents; 3D spheroid invasion
• Online Access: https://www.mdpi.com/1660-3397/16/11/442

Breast tumors reprogram their cellular metabolism, nutrient uptake, and utilization-associated biochemical processes. These processes become further transformed as genetically predisposed metastatic breast tumor cells colonize specific organs. Breast tumor cells often metastasize to the brain, bone, lung and liver. Massagué and colleagues isolated organotropic subclones and established organ-specific gene signatures associated with lung-, bone-, and brain-specific metastatic triple-negative breast cancer (TNBC) MDA-MB-231 cells. Using these genetically characterized metastatic subclones specific to lung (LM4175), bone (BoM1833), and brain (BrM-2a), we evaluated marine natural products for the ability to differentially suppress metastatic breast cancer cells in a target organ-dependent manner. Psammaplin-based histone deacetylase (HDAC) inhibitors were found to differentially inhibit HDAC activity, induce activation of hypoxia-inducible factor-1 (HIF-1), and disrupt organotropic metastatic TNBC subclone growth. Further, psammaplins distinctly suppressed the outgrowth of BoM1833 tumor spheroids in 3D-culture systems. Similar results were observed with the prototypical HDAC inhibitor trichostatin A (TSA). These organotropic tumor cell-based studies suggest the potential application of HDAC inhibitors that may yield new directions for anti-metastatic breast tumor research and drug discovery.